Research into new peptide therapeutics continues its growth, with more than 150 peptides in clinical development and 400–600 peptides undergoing preclinical studies.
TORONTO (PRWEB)
October 27, 2021
The interest in peptide therapeutics has increased considerably in the last decades due to the unique properties of this class of molecules, which are ideal to address challenging drug targets, in particular protein-protein interactions. Research into new peptide therapeutics continues its growth, with more than 150 peptides in clinical development and 400–600 peptides undergoing preclinical studies.
In this webinar, the featured speakers will outline how experience gained
by working on a wide variety of peptide drug discovery programs can guide and inform the early implementation of the optimal screening funnel to develop a safe and effective peptide drug.
They will describe the importance of identifying high-quality hits/leads through phage display libraries and will demonstrate how improved synthetic capabilities allows for the generation of complex molecules with strong potency, long half-life and high bioavailability. The speakers will also show how the hit to lead process can be accelerated and optimized by the timely identification of potential issues, including metabolic soft spots, pseudo-allergic potential, and aggregation propensity and how incorporating additional tools early on is critical to increasing the efficiency and rate of success of the peptide discovery process.
Join expert speakers from IRBM SpA, Silvia Peretti, PhD, Research Investigator, Display Technologies Unit; and Stefania Colarusso, Senior Research Investigator, in a live webinar on Tuesday, November 9, 2021 at 1pm EST (10am PST) for a discussion on the repertoire of assays and tools that the expert speakers commonly adopt to address specific issues relating to peptide therapeutics discovery.
For more information, or to register for this event, visit Peptide Therapeutics: Why Early Implementation of a Screening Funnel Is Key to Success.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Share article on social media or email: